HETLIOZ LQ
Live / Registered — Registered (as of 23 Aug 2022)
What this means for you
Registered since 23 Aug 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90288233
- Registration number
- 6828605
- Mark type
- Stylized text
- Filed
- 29 Oct 2020
- Published for opposition
- 11 May 2021
- Registered
- 23 Aug 2022
- Attorney of record
- Jayme M. Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, in liquid form and containing tasimelteon, for use in the treatment of diseases and disorders of the central nervous system, diseases and disorders having an impact on the central nervous system, diseases and disorders having a central nervous system manifestation, diseases and disorders of the circadian rhythm, diseases and disorders having an impact on circadian rhythm, and diseases and disorders having a circadian rhythm manifestation
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prior registrations
Prosecution history
- 23 Aug 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 23 Aug 2022 — REGISTERED-PRINCIPAL REGISTER
- 21 Jul 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 20 Jul 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 28 Jun 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Jun 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 17 Jun 2022 — USE AMENDMENT FILED
- 27 Jun 2022 — SOU EXTENSION 2 GRANTED
- 17 Jun 2022 — SOU EXTENSION 2 FILED
- 27 Jun 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 17 Jun 2022 — SOU TEAS EXTENSION RECEIVED
- 17 Jun 2022 — TEAS STATEMENT OF USE RECEIVED
- 29 Dec 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Dec 2021 — SOU EXTENSION 1 GRANTED
- 27 Dec 2021 — SOU EXTENSION 1 FILED